ArticleNPJ breast cancer2020
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.
Article in NPJ breast cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 81 citations in OpenAlex.
- Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance).Breast cancer research : BCR · 2025Trial
- Integrative machine learning reveals a TLS signature and CCL5-CCR1 axis-associated immune remodeling in breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- A framework for jointly modeling the natural history of ductal carcinoma in situ and invasive breast cancer.Journal of mathematical biology · 2026Article
- Racial Disparity in Ductal Carcinoma in Situ: Risk-Predictive and Actionable Biomarkers for Early Intervention.Cancers · 2026Review
- Spatial proteomics of breast ductal carcinoma in situ reveal distinct regional differences.Scientific reports · 2026Article
- Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis.Nature communications · 2026Article
- The role of magnetic resonance imaging (MRI) in breast cancer molecular subtypes.Polish journal of radiology · 2026Review
- Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming.Cancer biology & therapy · 2025Article
- Clinicopathological Significance of Transcription Factor p73 in Breast Cancers: Protein Expression and Transcriptomic Study.Biomedicines · 2025Article
- Generative and integrative modeling for transcriptomics with formalin fixed paraffin embedded material.Journal of translational medicine · 2025Article
- Mutational landscape of pure ductal carcinoma in situ and associations with disease prognosis and response to radiotherapy.Breast cancer research : BCR · 2025Article
- B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses.Breast cancer research : BCR · 2025Article
- Multimodal genome-wide survey of progressing and non-progressing breast ductal carcinoma in-situ.Breast cancer research : BCR · 2024Article
- Cytokine levels in breast cancer are highly dependent on cytomegalovirus (CMV) status.Breast cancer research and treatment · 2024Article
- The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma.Breast cancer research : BCR · 2024Article
- Accurate and efficient integrative reference-informed spatial domain detection for spatial transcriptomics.Nature methods · 2024Article
- Spatial Biology of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2024Review
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.Signal transduction and targeted therapy · 2024Review
- Article
- Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.Cancer cell · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 10 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ductal carcinoma in situ (DCIS) is a non-invasive type of breast cancer with highly variable potential of becoming invasive and affecting mortality. Currently, many patients with DCIS are overtreated due to the lack of specific biomarkers that distinguish low risk lesions from those with a higher risk of progression. In this study, we analyzed 57 pure DCIS and 313 invasive breast cancers (IBC) from different patients. Three levels of genomic data were obtained; gene expression, DNA methylation, and DNA copy number. We performed subtype stratified analyses and identified key differences between DCIS and IBC that suggest subtype specific progression. Prominent differences were found in tumors of the basal-like subtype: Basal-like DCIS were less proliferative and showed a higher degree of differentiation than basal-like IBC. Also,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.